236 results
Page 6 of 12
8-K
v2v ck7jhaz
20 Jul 22
Regulation FD Disclosure
6:07am
425
2qff3r
28 Jun 22
Business combination disclosure
4:03pm
8-K
2gv5g ip1es
28 Jun 22
Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer
4:02pm
8-K
EX-99.1
ena2h7
28 Jun 22
Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer
4:02pm
425
beyoin
17 Jun 22
Business combination disclosure
4:03pm
8-K
EX-99.1
z130sym b5qf6
17 Jun 22
Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit
4:02pm
8-K
awkx1c2w
17 Jun 22
Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit
4:02pm
425
vdvdddvx0f
6 Jun 22
Business combination disclosure
4:05pm
8-K
EX-2.6
radchr 1p
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-2.1
xhav9qcjg
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-99.2
1h7v3s7k
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-99.1
kdqlma
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-2.2
duk wrpikvec67n
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
82ogfxny57qaezjip
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-10.1
a7v3ueail ud5g7gul47
18 May 22
Termination of a Material Definitive Agreement
4:06pm
DEFA14A
71ek05k vnetac5ehx
25 Apr 22
Additional proxy soliciting materials
4:03pm
8-K
EX-10.1
wel9q u4167ih
4 Mar 22
Entry into a Material Definitive Agreement
4:15pm